DMD and Duchenne muscular dystrophy: Leveraging this chemistry, Daiichi-Sankyo has developed an ASO named DS-5141B, designed to induce dystrophin mRNA exon 45 skipping for the treatment of DMD (Takaishi et al., 2017, Daiichi Sankyo Co., 2023).